Marshall Wace LLP purchased a new position in shares of Novartis AG (NYSE:NVS) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 15,169 shares of the company’s stock, valued at approximately $1,259,000.

A number of other hedge funds also recently made changes to their positions in NVS. Parnassus Investments CA raised its position in Novartis AG by 89.4% in the first quarter. Parnassus Investments CA now owns 8,173,974 shares of the company’s stock worth $593,720,000 after buying an additional 3,858,632 shares in the last quarter. BlackRock Inc. acquired a new position in Novartis AG during the first quarter worth approximately $210,378,000. Janus Capital Management LLC raised its position in Novartis AG by 34,406.2% in the first quarter. Janus Capital Management LLC now owns 1,759,816 shares of the company’s stock worth $130,696,000 after buying an additional 1,754,716 shares in the last quarter. Wells Fargo & Company MN raised its position in Novartis AG by 12.2% in the first quarter. Wells Fargo & Company MN now owns 9,100,801 shares of the company’s stock worth $675,917,000 after buying an additional 988,301 shares in the last quarter. Finally, Karp Capital Management Corp acquired a new position in Novartis AG during the first quarter worth approximately $51,745,000. Hedge funds and other institutional investors own 10.97% of the company’s stock.

Novartis AG (NYSE NVS) opened at 82.74 on Thursday. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90. The stock’s 50 day moving average price is $83.94 and its 200 day moving average price is $79.45. The firm has a market cap of $193.85 billion, a price-to-earnings ratio of 30.21 and a beta of 0.73.

Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion during the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. Novartis AG’s revenue for the quarter was down 1.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.23 earnings per share. On average, equities research analysts predict that Novartis AG will post $4.74 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “15,169 Shares in Novartis AG (NVS) Acquired by Marshall Wace LLP” was published by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/15169-shares-in-novartis-ag-nvs-acquired-by-marshall-wace-llp/1533353.html.

A number of equities analysts have commented on the company. UBS AG reissued a “neutral” rating on shares of Novartis AG in a research note on Tuesday, May 30th. BidaskClub lowered Novartis AG from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis AG in a research note on Thursday, June 8th. Cowen and Company set a $90.00 price objective on Novartis AG and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Finally, TheStreet raised Novartis AG from a “c+” rating to a “b” rating in a research note on Friday, June 2nd. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $83.56.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the stock in a transaction on Wednesday, July 5th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.01% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.